Hassan Mohamed Kamel, Watari Hidemichi, Mitamura Takashi, Mohamed Zainab, El-Khamisy Sherif F, Ohba Yusuke, Sakuragi Noriaki
Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo, JAPAN ; Bitechnology Program, Zoology Department, Faculty of Science, Port Said University, Port Said, EGYPT ; Center of Genomics, Hemly Institute for Medical Sciences, Zewail City for Science and Technology, Giza, EGYPT.
Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo, JAPAN.
Oncoscience. 2015 Mar 23;2(3):294-308. doi: 10.18632/oncoscience.143. eCollection 2015.
MicroRNAs (miRNAs) have been reported to regulate the development of chemoresistance in many tumors. Stathmin 1 (STMN1) is a microtubule-depolymerizing molecule, involved in chemo-response; however, the mechanism of its regulation is unknown. Herein, the immunohistochemical study indicated significant upregulation of the STMN1 in the ovarian cancer tissues defined as resistant tumors compared with those defined as responsive tumors. STMN1 level elevated in the chemoresistant ovarian cancer cells, KF-TX, compared with the parental, KF, ones. Targeting STMN1 by siRNA restored taxane-sensitivity of KF-TX cells. Screening miRNA profiles from KF/KF-TX cellular set followed by bioinformatics-based prediction, revealed that miR-31 could be a possible regulator of STMN1. Down-modulation of miR-31 was verified by quantitative RT-PCR in the cellular set used. Overexpression of miR-31 in KF-TX cells (KF-TX-miR-31) significantly restored chemo-response and reduced STMN1 expression as well. STMN1 reduction-associated cellular characteristics such as enhanced microtubule polymerization and stability, as indicated by acetylated tubulin quantification, confocal visualization, and G2 phase delay, were observed in KF-TX-miR-31 cells, indicating the functional reduction of STMN1. miR-31 suppressed the luciferase activity in reporter construct containing the STMN1 3'-untranslated region (3'-UTR), confirming that miR-31 directly targets STMN1. miR-31 has therapeutic potency when introduced into ovarian cancer, in combination with taxane.
据报道,微小RNA(miRNA)可调节多种肿瘤的化疗耐药性发展。Stathmin 1(STMN1)是一种微管解聚分子,参与化疗反应;然而,其调控机制尚不清楚。在此,免疫组织化学研究表明,与被定义为反应性肿瘤的组织相比,被定义为耐药肿瘤的卵巢癌组织中STMN1显著上调。与亲本KF细胞相比,化疗耐药的卵巢癌细胞KF-TX中STMN1水平升高。通过小干扰RNA(siRNA)靶向STMN1可恢复KF-TX细胞对紫杉烷的敏感性。从KF/KF-TX细胞组中筛选miRNA谱,随后进行基于生物信息学的预测,结果显示miR-31可能是STMN1的一个潜在调节因子。在所使用的细胞组中,通过定量逆转录聚合酶链反应(RT-PCR)验证了miR-31的下调。在KF-TX细胞(KF-TX-miR-31)中过表达miR-31可显著恢复化疗反应,并降低STMN1的表达。在KF-TX-miR-31细胞中观察到与STMN1减少相关的细胞特征,如通过乙酰化微管蛋白定量、共聚焦显微镜观察和G2期延迟所表明的微管聚合和稳定性增强,这表明STMN1的功能降低。miR-31抑制了含有STMN1 3'-非翻译区(3'-UTR)的报告基因构建体中的荧光素酶活性,证实miR-31直接靶向STMN1。当与紫杉烷联合引入卵巢癌时,miR-31具有治疗潜力。